ArticleTranslational cancer research2026
Elevated TARDBP expression correlates with an unfavorable prognosis, immune evasion, and poor immune efficacy in hepatocellular carcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transactivation response element DNA-binding protein (TARDBP), encoding TDP-43, contributes to multiple oncogenic processes, yet its prognostic and immunological significance in hepatocellular carcinoma (HCC) remains unclear. This study aimed to comprehensively characterize TARDBP expression, its clinical correlations, and its role in the tumor immune microenvironment (TIME). Methods: TARDBP expression was analyzed using The Cancer Genome Atlas (TCGA) data and validated by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) in clinical specimens. Functional enrichment analyses were performed to identify associated signaling pathways. Correlations with immune modulators, tumor mutational burden (TMB), microsatellite instability (MSI), immunophenoscores, and drug sensitivity were systematically evaluated. Single-cell RNA sequencing was employed to map TARDBP expression across distinct cell subsets. Multiplex immunofluorescence was utilized to investigate the spatial relationship between TARDBP and immune cell infiltration. Results: TARDBP was significantly upregulated in HCC tissues and correlated with advanced tumor stage and poor prognosis. Single-cell analysis revealed that TARDBP expression was minimal in immune cells but highly enriched in invasive and proliferative tumor phenotypes. Experimentally, TARDBP knockdown attenuated oxaliplatin-induced nuclear factor-κB (NF-κB) activation and reduced programmed cell death ligand 1 (PD-L1) levels, suggesting a tumor-intrinsic mechanism of immune evasion. Clinically, elevated TARDBP expression correlated with lower immunophenoscores, higher TMB, poor overall survival, and reduced response to immune checkpoint blockade. Conclusions: High TARDBP expression in HCC confers a poor prognosis and is associated with an immunosuppressive microenvironment characterized by impaired immune cell infiltration. These findings suggest that TARDBP serves as a viable prognostic biomarker and a potential therapeutic target for enhancing immunotherapy efficacy in HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.